Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron PharmafiledCriticalRegeneron Pharma
Publication of MA30535B1publicationCriticalpatent/MA30535B1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Un anticorps humain ou un fragment d'attache d'antigène qui lie le récepteur IL-6 humain (hIL-6R) avec un KD d'environ 500 pM ou moins et bloque l'activité de l'IL-6 avec un IC50 d'environ 200 pM ou moins. Le fragment d'anticorps lie l'hIL-6R avec une affinité au moins 2 fois élevée relativement à son attache à l'IL-6R du singe.A human antibody or antigen-binding fragment that binds the human IL-6 receptor (hIL-6R) with a KD of about 500 μM or less and blocks the activity of IL-6 with an IC50 of about 200 μM or less. The antibody fragment binds hIL-6R with at least 2-fold affinity for its attachment to monkey IL-6R.
MA31519A2006-06-022008-12-26
ANTIBODIES AGAINST THE HIGH-AFFINITY HUMAN IL-6 RECEPTOR FOR THIS RECEPTOR
MA30535B1
(en)
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
antibody or antigen-binding fragment thereof, pharmaceutical composition, immunoconjugate, hybridoma, monoclonal antibody, and use of an antibody or antigen-binding fragment thereof